Some mushroom compounds, mainly beta-glucans, act on immune cells in ways that touch inflammatory pathways. But most of that evidence comes from cell and animal studies, not people. Only a small number of species have been tested in human trials for anything related to inflammation, and the results are limited, mixed, or tied to specific conditions like cancer treatment rather than general inflammation.
Read This Before the Research: Who Should Talk to a Clinician First
Mushroom compounds that act on the immune system can, in theory, interact with immune-related medical situations. Talk to a doctor or pharmacist before using mushroom supplements if any of the following apply to you.
- You take immunosuppressant medication, including drugs prescribed after an organ transplant. Substances that stimulate immune activity may work against these medications.
- You have an autoimmune condition, such as rheumatoid arthritis, lupus, or multiple sclerosis. Immune-active compounds could theoretically affect disease activity.
- You take blood thinners or have a bleeding disorder. Some mushroom species have been flagged for possible effects on blood clotting in isolated reports.
- You have surgery scheduled. Some clinicians advise stopping mushroom supplements beforehand because of the immune and clotting questions above.
- You are pregnant, breastfeeding, or considering pregnancy. Human safety data in these groups is limited to absent for most species.
- You have a mushroom or mold allergy, or a known liver condition. A small number of case reports describe liver-related reactions to certain mushroom supplements.
None of this means these mushrooms are known to be unsafe for these groups. It means the research to rule out a problem largely does not exist yet, so a clinician who knows your full health picture is the right person to weigh in.
What “Anti-Inflammatory” Means in Mushroom Research
Most medicinal mushrooms contain polysaccharides called beta-glucans in their cell walls. In lab studies, these compounds interact with immune cells such as monocytes, natural killer cells, and dendritic cells. That interaction is a biological mechanism. It is not the same as proof that eating a mushroom, or taking a mushroom supplement, meaningfully lowers inflammation in a person’s body.
The National Cancer Institute’s overview of medicinal mushrooms notes that mushroom polysaccharides are studied mainly for how they affect immune system activity, including natural killer cell and T-cell function, rather than for a direct anti-inflammatory effect in the way that term is typically used in inflammation research. (National Cancer Institute, PDQ Mushrooms summary)
This matters because “boosts the immune system” and “reduces inflammation” are not always the same thing. Immune activation can sometimes increase certain inflammatory signals rather than reduce them. Research that specifically measures inflammatory markers, like C-reactive protein or cytokine levels, in human subjects is what would answer the anti-inflammatory question directly. That kind of research is still limited for most species.
Evidence By Species: A Quick Comparison
Here is how the human and preclinical evidence compares across the species most often marketed for inflammation.
- Turkey tail. Human evidence: strongest of any species here, but almost entirely in cancer patients receiving chemotherapy, measuring immune function and survival, not general inflammation. Preclinical evidence: extensive; the beta-glucan PSK is linked to natural killer and T-cell activity. Mostly studied for: immune support alongside cancer treatment.
- Reishi. Human evidence: small trials with mixed results; some show immune parameter changes, others show none. Preclinical evidence: the most extensive of any species covered here. Mostly studied for: general immune modulation.
- Oyster mushroom. Human evidence: a 2026 randomized controlled trial measured inflammatory markers, mood, cognition, and metabolic outcomes directly in healthy older adults, one of the few trials to use inflammation as a stated outcome rather than a side finding. Preclinical evidence: ergothioneine content studied as an antioxidant and possible anti-inflammatory compound. Mostly studied for: direct inflammatory marker research, still an early body of work.
- Lion’s mane. Human evidence: very limited; small trials mostly focus on cognitive and mood outcomes, not inflammation. Preclinical evidence: some cell and animal data on nerve growth factor and inflammatory pathways. Mostly studied for: cognitive and neurological research.
- Chaga. Human evidence: essentially no human clinical trials on inflammation. Preclinical evidence: cell and animal studies on antioxidant and immune activity. Mostly studied for: preclinical antioxidant research.
- Cordyceps. Human evidence: trials exist mainly for exercise performance, not inflammation. Preclinical evidence: cell and animal studies on immune and inflammatory pathways. Mostly studied for: exercise and stamina research.
- Maitake. Human evidence: very limited. Preclinical evidence: beta-glucan research on immune activation. Mostly studied for: preliminary immune research.
- Shiitake. Human evidence: limited; the best-documented human effect is an allergic skin reaction called flagellate dermatitis, not an immune or inflammatory benefit. Preclinical evidence: lentinan, a shiitake polysaccharide, studied in cell and animal immune research. Mostly studied for: food-based nutrition and preliminary immune research.
For a closer look at how these species compare on immune-system research specifically, see the site’s cross-species immune function research guide.
Human Clinical Evidence: What Has Actually Been Tested in People
Turkey tail has the most human research of any mushroom species discussed here, but nearly all of it comes from cancer treatment studies, not general inflammation research. A review of eight randomized trials involving more than 8,000 gastric cancer patients found that adding the turkey tail extract PSK to chemotherapy was associated with longer survival compared to chemotherapy alone. Similar patterns appeared in colorectal and lung cancer trials, with outcomes including immune function measures, body weight, and survival, not inflammation markers specifically. (National Cancer Institute, PDQ Mushrooms summary)
Reishi has been tested in smaller human trials. One mechanistic study in lung cancer patients found that a reishi polysaccharide extract did not significantly change immune parameters as a group, though some individual patients showed changes. A separate trial on colorectal adenomas found a reduction in adenoma number and size after 12 months with a reishi extract. Neither trial measured inflammation directly. (National Cancer Institute, PDQ Mushrooms summary)
Oyster mushroom is one of the few species with a trial designed around inflammation as a direct outcome. A 2026 randomized controlled study published in the journal Food and Function tested oyster mushroom intake in healthy older adults and measured inflammatory markers alongside cognitive, mood, and metabolic outcomes. This is a newer and smaller body of research than the turkey tail cancer trials, and it has not yet been replicated widely.
For every other species covered on this site, human trials measuring inflammation specifically are either very small, focused on a different outcome entirely, or do not exist yet.
Preclinical Evidence: What Cell and Animal Studies Show
Most of what gets called “anti-inflammatory” in mushroom marketing comes from preclinical research. In cell studies, beta-glucans and other mushroom compounds can activate or modulate immune cell signaling in ways related to inflammation. In animal studies, some extracts have reduced markers of inflammation in specific disease models.
This is true for lion’s mane, chaga, cordyceps, and maitake in particular, where the bulk of the anti-inflammatory research is preclinical rather than clinical. A finding in cells or animals shows a possible mechanism. It does not confirm that the same compound, at a dose a person could realistically take, produces the same effect in a human body. Digestion, absorption, and dosing all change dramatically between a petri dish and a person.
The site’s evidence hierarchy guide walks through exactly how to read the difference between these study types, including common ways marketing claims blur the line between them.
Species With the Most Evidence vs. the Least
- Most human evidence: Turkey tail, almost entirely in cancer treatment settings. See the full turkey tail research and safety profile for details on PSK and PSP.
- Most preclinical evidence: Reishi, with extensive cell and animal data but modest and mixed human results.
- Newest direct inflammation research: Oyster mushroom, with a 2026 human trial measuring inflammatory markers as a stated outcome.
- Least human evidence overall: Chaga and maitake, where anti-inflammatory claims rest almost entirely on cell and animal studies.
Evidence Limits to Keep in Mind
A few limits apply across nearly all of this research.
Study sizes are often small, sometimes a few dozen people. Extract types, doses, and preparation methods vary widely between studies, which makes results hard to compare or generalize to a store-bought supplement. Most positive human trials involve people with a specific illness, like cancer, and cannot be assumed to apply to a healthy person taking a supplement for general wellness. Dietary supplements are not required to prove effectiveness before they reach the market, and ingredient amounts can vary between lot and product. (National Cancer Institute, PDQ Mushrooms summary)
Finally, “anti-inflammatory” is often used loosely in marketing to describe any immune-related finding, even when the underlying study measured something else, like natural killer cell activity or tumor markers. Readers who want to check a specific claim can search the primary literature directly through PubMed.
Frequently Asked Questions
Which mushroom has the strongest anti-inflammatory evidence in humans?
No single species has strong, direct human evidence for general anti-inflammatory effects. Turkey tail has the most human research overall, but it centers on immune function and survival in cancer patients, not inflammation specifically. Oyster mushroom has one of the few trials measuring inflammatory markers directly, and that research is still new.
Can mushroom supplements replace anti-inflammatory medication?
No. Mushroom supplements are not FDA-approved to treat, prevent, or replace medication for any inflammatory condition. Anyone considering changing or stopping a prescribed medication should talk with the clinician who prescribed it first.
Is a lab or animal study enough to trust an anti-inflammatory claim?
Not on its own. A cell or animal finding shows a possible mechanism, not a proven effect in people. It is a useful early signal, but it needs human trials to confirm whether the same effect happens at a realistic dose in a real body.
Are mushroom supplements safe to combine with other supplements or medications?
It depends on the person and the product, and this article is not a substitute for that check. Anyone taking immune-affecting medication, blood thinners, or managing an autoimmune condition should ask a doctor or pharmacist before adding a mushroom supplement.
Educational Disclaimer
This article is for general education only. It is not medical advice, and it does not diagnose, treat, or promise results for any condition. Mushroom supplements are not approved by the FDA to treat, cure, or prevent any disease, including inflammatory conditions. Always talk with a qualified healthcare provider before starting, stopping, or changing any supplement or medication, especially if you have a medical condition, take prescription drugs, or are pregnant or breastfeeding.